HC Wainwright Analysts Raise Earnings Estimates for CRSP

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at HC Wainwright increased their Q2 2025 EPS estimates for shares of CRISPR Therapeutics in a report issued on Wednesday, May 7th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.93) per share for the quarter, up from their prior forecast of ($1.01). HC Wainwright has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.07) EPS and FY2025 earnings at ($4.57) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. The company’s quarterly revenue was up 71.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.43) earnings per share.

A number of other brokerages have also commented on CRSP. Stifel Nicolaus decreased their price target on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a report on Thursday, February 13th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Friday, March 21st. Royal Bank of Canada decreased their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 12th. Chardan Capital decreased their target price on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Finally, Barclays cut their price target on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating for the company in a research report on Friday. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and an average price target of $71.75.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $37.59 on Monday. The company’s fifty day moving average price is $38.03 and its 200-day moving average price is $42.64. The firm has a market capitalization of $3.25 billion, a price-to-earnings ratio of -8.60 and a beta of 1.88. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $67.88.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, COO Julianne Bruno sold 1,198 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the transaction, the chief operating officer now owns 8,263 shares of the company’s stock, valued at $350,516.46. This represents a 12.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,381 shares of company stock worth $1,608,243. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds have recently made changes to their positions in the company. Costello Asset Management INC bought a new position in CRISPR Therapeutics in the first quarter worth $27,000. Wood Tarver Financial Group LLC purchased a new position in CRISPR Therapeutics during the 4th quarter valued at about $30,000. Ameriflex Group Inc. bought a new stake in CRISPR Therapeutics during the fourth quarter worth about $36,000. Western Pacific Wealth Management LP grew its stake in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after buying an additional 500 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of CRISPR Therapeutics during the third quarter valued at $40,000. 69.20% of the stock is currently owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.